InnoCan Pharma Corporation Stock price

Equities

INNO

CA45783P1027

Pharmaceuticals

Delayed Canadian Securities Exchange 11:22:14 2024-03-28 am EDT 5-day change 1st Jan Change
0.3 CAD -6.25% Intraday chart for InnoCan Pharma Corporation +1.69% -3.23%
Sales 2021 0.2 0.27 Sales 2022 2.56 3.48 Capitalization 39.6M 53.9M
Net income 2021 -10M -13.61M Net income 2022 -3M -4.08M EV / Sales 2021 802,166,532 x
Net cash position 2021 11.05 15.04 Net cash position 2022 4.91 6.69 EV / Sales 2022 15,473,821 x
P/E ratio 2021
-14.1 x
P/E ratio 2022
-10.5 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 76.14%
More Fundamentals * Assessed data
Dynamic Chart
InnoCan Pharma "Paves Its Way" to LPT-CBD Chemistry, Manufacturing and Controls (CMC), "Key Milestones" for FDA Approval MT
InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding CI
Innocan Pharma Corporation Announces Tissue Distribution Study of LPT-CBD to the Brain CI
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding CI
InnoCan Pharma Corporation Announces Study Findings That Lpt-Cbd Maintain Its Prolonged Release in Rabbits CI
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
InnoCan Pharma Brief: Says "Surge" in revenue Primarily attributable to "Robust" sales performance of Subsidiary, B.I. Sky Global Ltd. MT
InnoCan Pharma Brief: Reporting US$4.083 Million In Revenues for Q3 2023 Vs US$749,000 for Q3 2022, representing an increase of 445% MT
Innocan Pharma Corporation Announces Promising LPT-CBD Safety Indications CI
InnoCan Pharma Completes Second, Final Tranche of Financing; Down Over 3% MT
InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding CI
InnoCan Pharma Completes First Tranche Private Placement; Down 4.8% MT
Innocan Pharma Plans Brokered LIFE Offering of Units for Nearly $3 Million MT
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding CI
InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board CI
More news
1 week+6.67%
3 months+12.28%
6 months+4.92%
Current year+3.23%
More quotes
1 week
0.27
Extreme 0.265
0.32
1 month
0.27
Extreme 0.265
0.33
Current year
0.26
Extreme 0.255
0.34
1 year
0.18
Extreme 0.18
0.52
3 years
0.18
Extreme 0.18
1.65
5 years
0.05
Extreme 0.05
1.65
10 years
0.05
Extreme 0.05
1.65
More quotes
Managers TitleAgeSince
Founder 71 -
Founder - 18-05-30
Founder 59 18-05-30
Members of the board TitleAgeSince
Founder 59 18-05-30
Director/Board Member 64 20-01-21
Chairman 59 14-05-31
More insiders
Date Price Change Volume
24-03-28 0.3 -6.25% 65 000
24-03-27 0.32 +3.23% 300,949
24-03-26 0.31 +8.77% 185,000
24-03-25 0.285 +1.79% 24,500
24-03-22 0.28 -5.08% 3,750

Delayed Quote Canadian Securities Exchange, March 27, 2024 at 03:59 pm EDT

More quotes
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
More about the company
  1. Stock
  2. Equities
  3. Stock InnoCan Pharma Corporation - Canadian Securities Exchange